top of page

Search Results

Results found for "Owen P. McGuinness"

  • Dr. Thomas P. Sakmar receives an honorary doctorate from Karolinska Institute

    November 2021 "So proud and grateful to receive honorary doctorate yesterday from Karolinska Institute and celebrate with my family in Stockholm." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids

    September 2022 "Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) lipids have been shown to stabilize an active conformation of class A G-protein coupled receptors (GPCRs) through a conserved binding site, not present in class B GPCRs. For class B GPCRs, previous molecular dynamics (MD) simulation studies have shown PI(4,5)P2 interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics. In this work, we applied MD simulations supported by native mass spectrometry (nMS) to study lipid interactions with GCGR. We demonstrate how tail composition plays a role in modulating the binding of PI(4,5)P2 lipids to GCGR. Specifically, we find the PI(4,5)P2 lipids to have a higher affinity toward the inactive conformation of GCGR. Interestingly, we find that in contrast to class A GPCRs, PI(4,5)P2 appear to stabilize the inactive conformation of GCGR through a binding site conserved across class B GPCRs but absent in class A GPCRs. This suggests differences in the regulatory function of PI(4,5)P2 between class A and class B GPCRs." Read more at the source #DrGPCR #GPCR #IndustryNews

  • PI(4,5)P 2-stimulated positive feedback drives the recruitment of Dishevelled to Frizzled in Wnt-β-c

    September 2022 "In the Wnt-β-catenin pathway, Wnt binding to Frizzled (Fzd) and LRP5 or LRP6 (LRP5/6) co-receptors inhibits the degradation of the transcriptional coactivator β-catenin by recruiting the cytosolic effector Dishevelled (Dvl). Polymerization of Dvl at the plasma membrane recruits the β-catenin destruction complex, enabling the phosphorylation of LRP5/6, a key step in inhibiting β-catenin degradation. Using purified Fzd proteins reconstituted in lipid nanodiscs, we investigated the factors that promote the recruitment of Dvl to the plasma membrane. We found that the affinity of Fzd for Dvl was not affected by Wnt ligands, in contrast to other members of the GPCR superfamily for which the binding of extracellular ligands affects the affinity for downstream transducers. Instead, Fzd-Dvl binding was enhanced by increased concentration of the lipid PI(4,5)P2, which is generated by Dvl-associated lipid kinases in response to Wnt and which is required for LRP5/6 phosphorylation. Moreover, binding to Fzd did not promote Dvl DEP domain dimerization, which has been proposed to be required for signaling downstream of Fzd. Our findings suggest a positive feedback loop in which Wnt-stimulated local PI(4,5)P2 production enhances Dvl recruitment and further PI(4,5)P2 production to support Dvl polymerization, LRP5/6 phosphorylation, and β-catenin stabilization." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Dr. GPCR University registration is now open! Secure your spot now!

    GPCR University Early-Bird Registration Now Open for Premium Members!

  • Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling

    Nat Rev Neurosci, 2001. 2 (4): p. 274-86. 3.          Pharmacol Rev, 2016. 68 (4): p. 954-1013. 6.          Nature Communications, 2024. 15 (1): p. 4390. 7.          Mol Pharmacol, 2012. 81 (3): p. 309-18. 9.          Chem Rev, 2017. 117 (1): p. 111-138.

  • Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling

    Annu Rev Biochem, 1987. 56: p. 615-49. 2.      Cell, 2020. 182(3): p. 770-785.e16. 4.      Nature, 2020. 577(7790): p. 432-436. 6.      Nat Methods, 2005. 2(3): p. 177-84. 7.      Nat Protoc, 2006. 1(1): p. 337-45. 15.   

  • Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes

    Nat Rev Drug Discov, 2013. 12 (3): p. 205-16. 2.          Cell Metab, 2018. 27 (4): p. 740-756. 3.          Cell, 2016. 165 (7): p. 1632-1643. 6.          Nat Commun, 2015. 6 : p. 8918. 7.          Endocr Rev, 2023. 44 (3): p. 492-517. 8.         

  • ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

    oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned

  • All About Addgene: More Open and Reproducible Science with Materials Sharing

    Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. Joanne Kamens is our guest. If you need a plasmid for your research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe #addgene

  • Navigating the Signaling Network: RTK and GPCR Crosstalk Uncovered

    phosphorylation of the G protein subunit Gαi at specific residues within three strategic hotspots: the P Key findings include: Phosphorylation Hotspots: P Loop (Ser44, Ser47, Thr48): Impairs ligand-stimulated Signaling Pathway Segregation: Phosphorylation events in the interdomain cleft and P loop uncouple G These findings enhance our understanding of cellular signaling dynamics and open new avenues for therapeutic J., Ghassemian, M., Kufareva, I., & Ghosh, P. (2024).

  • Microbial Metabolites Orchestrate a Distinct Multi-Tiered Regulatory Network in the Intestinal Epith

    Expression "P-glycoprotein (P-gp) is a key component of the intestinal epithelium playing a pivotal secondary bile acids, produced by the intestinal microbiome, potentiate the induction of functional P-gp We now aim to determine the molecular mechanism by which this functional microbiome output regulates P-gp combination discovered a unique transcriptional program involving multiple pathways that converge on P-gp on a sophisticated signaling network directed by intestinal microbial metabolites that orchestrate P-gp

  • Pharmacological Properties and Function of PxOctβ3 Octopamine Receptor in Plutella xylostella (L.)

    The open reading frame (ORF) of PxOctβ3 was phylogenetically analyzed, and the levels of expression of and an analysis using quantitative PCR showed that it was expressed at all developmental stages of P. of double-stranded RNA in an RNA interference assay indicated that PxOctβ3 regulates development in P. This study demonstrated the pharmacological properties and functions of PxOctβ3 in P. xylostella, thus

  • A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.

    .; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K.; Qu, L.; Han, G. W.; Iyer, M. V.; Van Der Stelt, M.; Pacher, P.; Gertsch, J.; Ullmer, C.; McCormick, P. J.; Oddi, S.; Spaink, H. P.; Maccarrone, M.; Veprintsev, D. B.; Carreira, E. M.; Grether, U.; Nazaré, M. -P. -F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J.-P.

  • Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs)...

    clinical parameters such as alpha-fetoprotein and tumor grade in the HCC patients; (c) besides HCC (p was found to be an important factor for survival in four other cancers (clear renal cell carcinoma: p < 0.001, lung adenocarcinoma: p = 0.004, mesothelioma: p = 0.039, ovarian serous cystadenocarcinoma: p = 0.048); (d) RGS20 was found to be significantly associated with some tumor-related signaling pathways

  • Regulators of G-protein signaling: essential players in GPCR signaling

    Cell, 1997. 89(2): p. 251-61. https://pubmed.ncbi.nlm.nih.gov/9108480/ 2. Front Mol Neurosci, 2020. 13: p. 5. https://pubmed.ncbi.nlm.nih.gov/32038168/ 3. Cell, 2021. 184(4): p. 931-942.e18. https://pubmed.ncbi.nlm.nih.gov/33571431/ 6. J Neurosci, 2019. 39(42): p. 8291-8304. https://pubmed.ncbi.nlm.nih.gov/31308097/ 8. Genomics, 2021. 113(4): p. 2134-2144. https://pubmed.ncbi.nlm.nih.gov/33845140/

  • Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling

    GPCR priming opens new avenues for understanding the nuanced regulatory mechanisms governing GPCR signalling Proc Natl Acad Sci U S A, 2020. 117(35): p. 21723-21730. 2.      Proceedings of the National Academy of Sciences, 2017. 114(14): p. 3756-3761. 3.      Mol Pharmacol, 2017. 91(5): p. 533-544.

  • High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...

    of patients showed high GPER expression and significant correlation with the mRNA subtype of TNBC (P  = 0.001), total metastatic events (P = 0.019) and liver metastasis (P = 0.011). interval of 67.1 months, a significant trend towards reduced distant metastasis-free survival (DMFS) (P

  • Nanobodies: New Dimensions in GPCR Signaling Research

    J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). D., Tworak, A., Watanabe, K., Pardon, E., Steyaert, J., Kandori, H., Katayama, K., Kiser, P.

  • β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...

    biosensors reveals distinct conformational signatures of β-arrestin1 and 2 when bound to active PTH1R (P-R Here, we show differences between conformational changes that are induced by P-R* or R* receptor states

  • An overview of the compartmentalized GPCR Signaling: Relevance and Implications

    P. (2009). Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. https://doi.org/10.1210/en.2015-1945 Irannejad, R., Pessino, V., Mika, D., Huang, B., Wedegaertner, P. I., Gerrikagoitia, I., Suarez, J., Rodríguez De Fonseca, F., Puente, N., Marsicano, G., & Grandes, P. Frontiers in physiology, 7, 476. https://doi.org/10.3389/fphys.2016.00476 Insel, P. P., Lowy, A. M., & Murray, F. (2018).

  • Inside Out: Mapping GPCRs from Membrane Codes to Market Moves

    Modulator for Non-Addictive Pain Relief   A Cell-Permeable Fluorescent Probe Illuminates Early PI(4,5)P

  • Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR

    P., Macdonald, C. B., Mehrota, E., Grimes, P. R., ... & Manglik, A. (2024).

  • The Perils and Guardrails of Modifying Signalling Proteins in Bioassays

    Hunter P. Persechino M, Hedderich JB, Kolb P, Hilger D. Changeux J-P, Christopoulos A. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Rößler P, Mayer D, Tsai CJ, Veprintsev DB, Schertler GFX, Gossert AD.

  • From DNA day to GPCR genomics

    integration of genomics with structural biology, pharmacology, bioinformatics, and clinical research has opened B., Panova, O., Hilger, D., Casiraghi, M., He, F., Maul, L., Gmeiner, P., Kobilka, B. K., Hildebrand, P. W., & Skiniotis, G. (2023).

  • Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    affinities from previous studies.[13] Besides traditional dopaminergic ligands, the affinities of the P- Therapeutics   2016 , 165 , 164–177. https://doi.org/10.1016/j.pharmthera.2016.06.007 . (2)         Sokoloff, P. P. U.; Lüdeke, S.; Koch, P.; Rinken, A.; Keller, M. T.; Schwille, P.; Jungmann, R.

  • Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...

    FLNA absence reduced the basal number of hetero-dimers (-36.8 ± 6.3% reduction of PLA events in M2, P both A7 and M2 (+20.0 ± 11.8% and +44.1 ± 16.3% increase of PLA events in A7 and M2, respectively, P

  • The sixth transmembrane region of a pheromone G-protein coupled receptor, Map3, is implicated in ...

    The fission yeast Schizosaccharomyces pombe has two mating types, Plus (P) and Minus (M). Here, we investigated the stringency of the two GPCRs, Mam2 and Map3, for their respective pheromones, P-factor

  • Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation

    M., Medel-Lacruz, B., Baidya, M., Makarova, M., Mistry, R., Goulding, J., Drube, J., Hoffmann, C., Owen Toxicol. 52, 179–197. https://doi.org/10. 1146/annurev.pharmtox.010909.105800 Tsao, P.

bottom of page